Low-dose aspirin and rivaroxaban combination therapy to overcome aspirin non-sensitivity in patients with vascular disease

Approximately 20% of vascular patients treated with acetyl salicylic acid (i.e., aspirin) demonstrate less than expected platelet inhibition – putting them at a four-fold increased risk of adverse cardiovascular events. Low-dose rivaroxaban (2.5 mg twice daily) in combination with low-dose aspirin h...

Полное описание

Библиографические подробности

Главные авторы:	Hamzah Khan, Mariya Popkov, Shubha Jain, Niousha Djahanpour, Muzammil H. Syed, Margaret L. Rand, John Eikelboom, C. David Mazer, Mohammed Al-Omran, Rawand Abdin, Mohammad Qadura
Формат:	Artigo
Язык:	Inglês
Опубликовано:	Frontiers Media S.A. 2022-08-01
Серии:	Frontiers in Cardiovascular Medicine
Предметы:	rivaroxaban aspirin antiplatelet non-sensitivity vascular
Online-ссылка:	https://www.frontiersin.org/articles/10.3389/fcvm.2022.912114/full
Метки:	Добавить метку Нет меток, Требуется 1-ая метка записи!